Delisting Risk Due to Audit Disclaimer... Treasury Stock Buyback and Cancellation Plan Completely Cancelled, Shareholder Value at Risk
Enzychem Lifesciences received a disclaimer of opinion on March 23, 2026 due to audit scope limitation, triggering a delisting reason and trading suspension by KRX. Consequently, the board canceled the planned 3 billion won treasury stock acquisition trust agreement on May 26.
The originally intended buyback of 2,846,299 shares (approx. 3 billion won) aimed at price stabilization and subsequent cancellation for shareholder value, but the delisting crisis made this impossible.
The company had fully canceled its remaining 425,327 treasury shares on March 13, 2026, now holding zero treasury shares (0%).
[AI Comprehensive Analysis]This disclosure illustrates the suspension of shareholder return policies amid actual delisting risks, with very high downside risk to enterprise value and liquidity. Investors must carefully assess the likelihood of delisting and potential recovery.
KOSDAQ Filing Information
Filing: [Correction of Description] Material Event Report (Decision on Execution of Trust Agreement for Acquisition of Treasury Shares)